Records 1 - 21
| Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Clinical lung cancer 2020 Oct .
Riess Jonathan W, Frankel Paul, Shackelford David, Dunphy Mark, Badawi Ramsey D, Nardo Lorenzo, Cherry Simon R, Lanza Ian, Reid Joel, Gonsalves Wilson I, Kunos Charles, Gandara David R, Lara Primo N, Newman Edward, Paik Paul
| Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non-small cell lung cancer.
Oncology reports 2020 Mar .
Hu Jing, Shang Yanhong, Shi Xiaoliang, Zhang Shuirong, Shi Junping, Yao Ming, Wang Aodi, Shou Tao, Shi Weiwei, Wang Kai, Liu Angen, Pan Xiaojie, Wang Yongj
| Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
The oncologist 2019 Nov .
Fang Wenfeng, Zhao Shen, Liang Ying, Yang Yunpeng, Yang Lin, Dong Xiaorong, Zhang Li, Tang Yong, Wang Shoufeng, Yang Yang, Ma Xiaoyan, Wang Minghui, Wang Wenjing, Zhao Songhui, Wang Kai, Gao Song, Zhang
| Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology 2019 Oct .
Xu Yiquan, Huang Yina, Weng Lihong, Zheng Jiankun, Huang Yi, Lin Ying, Zhao Yunan, Li Hongru, Chen Yushe
| Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
Journal of cancer research and clinical oncology 2019 Aug .
Deng Li-Li, Gao Ge, Deng Hong-Bin, Wang Feng, Wang Zhi-Hui, Yang
| Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet.
Bioscience reports 2019 Mar .
Ryu Jeong-Seon, Lim Jun Hyeok, Kim Hyun-Jung, Kim Min Jeong, Park Mi Hwa, Kim Jung S
| Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
Current cancer drug targets 2018 Oct .
Song Yuanyuan, Liu Peng, Huang Yu, Guan Yanfang, Han Xiaohong, Shi Yuank
| Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Lung cancer (Amsterdam, Netherlands) 2018 Jun 120 113-121.
Du Meijun, Thompson Jonathan, Fisher Hannah, Zhang Peng, Huang Chiang-Ching, Wang Lia
| Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Cancer 2018 Jan .
Ross Jeffrey S, Fakih Marwan, Ali Siraj M, Elvin Julia A, Schrock Alexa B, Suh James, Vergilio Jo-Anne, Ramkissoon Shakti, Severson Eric, Daniel Sugganth, Fabrizio David, Frampton Garrett, Sun James, Miller Vincent A, Stephens Philip J, Gay Laurie
| Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Lung cancer (Amsterdam, Netherlands) 2018 12 126 182-188.
Udagawa Hibiki, Umemura Shigeki, Murakami Isao, Mimaki Sachiyo, Makinoshima Hideki, Ishii Genichiro, Miyoshi Tomohiro, Kirita Keisuke, Matsumoto Shingo, Yoh Kiyotaka, Niho Seiji, Tsuchihara Katsuya, Goto Koic
| Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer.
Oncotarget 2017 Sep 8 (37): 61777-61785.
Kang Hyo Gyoung, Yoo Seung Soo, Choi Jin Eun, Hong Mi Jeong, Do Sook Kyung, Jin Cheng Cheng, Kim Soyoun, Lee Won Kee, Choi Sun Ha, Lee So Yeon, Kim Hyun Jung, Lee Shin Yup, Lee Jaehee, Cha Seung Ick, Kim Chang Ho, Seok Yangki, Lee Eungbae, Cho Sukki, Jheon Sanghoon, Park Jae Yo
| MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.
BioMed research international 2017 2017 6501385.
Jiang Wei, Zhang Wenjue, Wu Lihong, Liu Lipin, Men Yu, Wang Jingbo, Liang Jun, Hui Zhouguang, Zhou Zongmei, Bi Nan, Wang Luh
| Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Aug .
Miyoshi Tomohiro, Umemura Shigeki, Matsumura Yuki, Mimaki Sachiyo, Tada Satoshi, Ishii Genichiro, Udagawa Hibiki, Matsumoto Shingo, Yoh Kiyotaka, Niho Seiji, Ohmatsu Hironobu, Aokage Keiju, Hishida Tomoyuki, Yoshida Junji, Nagai Kanji, Goto Koichi, Tsuboi Masahiro, Tsuchihara Katsu
| Clinical correlation of extensive-stage small-cell lung cancer genomics.
Annals of oncology : official journal of the European Society for Medical Oncology 2016 Apr 27 (4): 642-7.
Dowlati A, Lipka M B, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey
| Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Oncotarget 2016 Apr .
Lim Sun Min, Kim Hye Ryun, Cho Eun Kyung, Min Young Joo, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil, Cho Byoung Chul, Lee Ji-Hyun, Jeong Hye Cheol, Kim Eun Kyung, Kim Joo-Ha
| A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors.
Cancer discovery 2015 Mar 5 (3): 245-54.
Van Rechem Capucine, Black Joshua C, Greninger Patricia, Zhao Yang, Donado Carlos, Burrowes Paul D, Ladd Brendon, Christiani David C, Benes Cyril H, Whetstine Johnathan
| PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
PloS one 2014 9 (2): e88291.
Wang Lei, Hu Haichuan, Pan Yunjian, Wang Rui, Li Yuan, Shen Lei, Yu Yongfu, Li Hang, Cai Deng, Sun Yihua, Chen Haiqu
| Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Nov 19 (22): 6252-60.
Li Qianxia, Yang Ju, Yu Qianqian, Wu Huanlei, Liu Bo, Xiong Huihua, Hu Guangyuan, Zhao Jing, Yuan Xianglin, Liao Zhongxi
| Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2013 Mar 22 (1): 1.
Schildgen V, Lüsebrink J, Appel JD, Wübben C, Engel-Riedel W, Ludwig C, Stoelben E, Schildgen O, Brockmann M
| Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Asian Pacific journal of cancer prevention : APJCP 2012 13 (5): 2157-62.
Xu Jia-Li, Wang Zhen-Wu, Hu Ling-Min, Yin Zhi-Qiang, Huang Ming-De, Hu Zhi-Bin, Shen Hong-Bing, Shu Yong-Qi
| PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2011 Jan 71 (1): 82-8.
Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xife